Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 45Other hematologic neoplasm 27Lymphoid 27Sarcoma 12Gastrointestinal 9CNS 8Thoracic 7Gynecologic 7Myeloid 6Dermatologic 6Genitourinary 5Breast 3Other solid neoplasm 2Tumor-Agnostic 1Head & Neck 1Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × selinexor × Endocrine × Clear all
NCT02250885 2019-09-17

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Gabrail Cancer Center Research

Phase 2 Completed
14 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡